**New York State Department of Health**

**CENTERS OF EXCELLENCE FOR ALZHEIMER’S DISEASE**

***Clinical Trials & Alzheimer’s Disease Research***

**Resources**

**2022-2023 Update – October 2022**

****

**CEAD RESEARCH CONTACT LIST**

|  |  |
| --- | --- |
| **SUNY at Buffalo**  **Kinga Szigeti MD, ADMDC Director**  [szigeti@buffalo.edu](mailto:szigeti@buffalo.edu)  716-323-0521  **Nicholas Audino**  [ncaudino@buffalo.edu](mailto:ncaudino@buffalo.edu)  716-323-0549 | **Montefiore Health System**  **Jessica Zwerling, MD, Project Director**  [jzwerlin@montefiore.org](mailto:jzwerlin@montefiore.org)  914-375-4880 |
| **University of Rochester**  **Carol Podgorski, PhD, Finger Lakes**  CEAD Director/Program Manager  [Carol\_podgorski@urmc.rochester.edu](mailto:Carol_podgorski@urmc.rochester.edu)  585-760-6607    **Susan Salem-Spencer RN, MSN, CCRC**  AD-CARE, The University of Rochester Medical Center  <https://www.urmc.rochester.edu/alzheimers-care>  585-602-5203 | **Columbia University Irving Medical Center**  **Lawrence S. Honig, MD, Program Director**  [Lh456@cumc.columbia.edu](mailto:Lh456@cumc.columbia.edu)  212-305-9194    **Betina Idnay, Research Nurse Coordinator**  Taub Institute for Research on Alzheimer’s Disease and the Aging Brain  [BSI2102@cumc.columbia.edu](mailto:BSI2102@cumc.columbia.edu)  212-342-5615 |
| **SUNY Upstate Medical University**  **Colleen Dillenbeck**  [dillenco@upstate.edu](mailto:dillenco@upstate.edu)  315-464-9014 | **New York University School of Medicine**  **Anaztasia Ulysse**  **Clinical Research Program Manager**  [anaztasia.ulysse@nyulangone.org](mailto:anaztasia.ulysse@nyulangone.org)  212-263-0771    **Karyn Marsh, PhD, LCSW**  Program Co-Director  [karyn.marsh@nyulangone.org](mailto:karyn.marsh@nyulangone.org)  212-263-2617 |
| **Glens Falls Hospital**  **Heather O’Connor, Program Director**  [hoconnor@glensfallshosp.org](mailto:hoconnor@glensfallshosp.org)  518-926-5016 | **Downstate Medical Center**  **Rajkumar Patel, MD**  [rajkumar.patel@downstate.edu](mailto:rajkumar.patel@downstate.edu)  718-270-8261 |
| **Albany Medical College**  **Nancy Cummings**  Executive Director/Program Manager  [cumminn@amc.edu](mailto:cumminn@amc.edu)  518-264-1047 | **Stony Brook University**  **Nikhil Palekar, MD, Director – Alzheimer’s Disease Clinical Trials Program**  [Nikhil.Palekar@stonybrookmedicine.edu](mailto:Nikhil.Palekar@stonybrookmedicine.edu)  631-954-2323 |

**Resources to Locate Information about Alzheimer’s Disease Clinical Trials and related Research**

**Resources for locating Clinical Trials and related research:**

1. [www.UsAgainstAlzheimers.org/research](http://www.UsAgainstAlzheimers.org/research)
2. [www.alz.org/trialmatch](http://www.alz.org/trialmatch)
3. [www.CenterWatch.com](http://www.CenterWatch.com)
4. [www.Clinicaltrials.gov](http://www.Clinicaltrials.gov)
5. <https://beta.clinicaltrials.gov/>

**Guide for Potential Participants of Clinical Trials and Research:**

Us Against Alzheimer’s Toolkit

This *Resource guide -* ***Curing Alzheimer’s; Clinical Trials Are Key -*** *outlines the benefits and importance of participating in clinical trials, ways to locate trail opportunities and what participants should expect when engaging in clinical trial. Several personal stories further support information about participation.*

**In English**: <https://www.usagainstalzheimers.org/sites/default/files/2019-02/toolkit_2.5.19_cover1_%281%29.pdf>

**In Spanish**: <https://www.usagainstalzheimers.org/sites/default/files/2019-06/Toolkit_Espanol_web.pdf>

**Online Surveys**

Brain Health Registry – [www.brainhealthregistry.org](http://www.brainhealthregistry.org)

*This registry is dedicated to the discovery of treatments for Alzheimer’s and other brain disorders. Health data and testing results are gathered from persons diagnosed with neurological diseases, including Alzheimer’s disease, care partners and other interested individuals.*

MindCrowd – [www.mindcrowd.org](http://www.mindcrowd.org)

*Take a 10-minute online test to help researchers see how genetic differences could affect brain-related diseases. This is open to all interested individuals.*

Us Against Alzheimer’s – A-List – [www.alist4research.org](http://www.alist4research.org)

*This is an online community for people with or at risk for Alzheimer’s disease and other dementias, as well as family and other interested individuals. Surveys are conducted on patient and caregiver preferences, patient-doctor relationships, clinical trials, caregiver health, and technology.*

All of Us Research Program – [www.joinallofus.org/en](http://www.joinallofus.org/en)

*Participation is open to all individuals over the age of 18 who are interested in supporting research. Health data is gathered to inform “precision medicine” and patient-centered approaches to health care. Researchers will explore factors like environment, lifestyle, and genetics.*

**Registries**

Alzheimer’s Prevention Registry (APR) – [www.endalznow.org](http://www.endalznow.org)

*When joining the Alzheimer's Prevention Registry, you will receive information about opportunities to take part in research studies, plus Alzheimer's news and research updates. (ages 50+).*

CARE Registry – <https://careregistry.ucsf.edu>

*Online registry for Asian Americans and Pacific Islanders who are interested in participating in research related to Alzheimer's disease and related dementias, aging, caregiving, and other health topics across the lifespan.*

Alzheimer’s Prevention Trials (APT) Webstudy - <https://www.aptwebstudy.org/>

*Online registry designed to accelerate enrollment into Alzheimer's clinical trials. Open to individuals 50 and older. Take online tests to assess memory and thinking skills, gain access to scores, and be notified of opportunities for in-person assessments and clinical trials.*

Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU) – <https://dian.wustl.edu>

*Help advance the understanding and treatment of Dominantly Inherited Alzheimer’s Disease by joining the DIAN clinical trial registry (must be 18+ and have at least 2 generations of family members who have experienced symptoms consistent with Alzheimer’s disease before the age of 60).*

**Tissue and Brain Donation**

National Alzheimer’s Association – <https://www.alz.org/alzheimers-dementia/research_progress/brain-donation>

*The Association offers guidance about brain and tissue donation and linkages to a variety of resources.*

Brain Donor Project – <https://braindonorproject.org>

*Pre-register to become a brain and tissue donor through this initiative.*

NIH NeuroBioBank – <https://neurobiobank.nih.gov/about/>

*The NeuroBioBank brain and tissue repositories distribute thousands of samples per year to the research community studying neurological, developmental, and psychiatric disorders.*

Brain Donation: A Gif for Future Generations – <https://www.nia.nih.gov/health/brain-donation-gift-future-generations>

*Learn about why people donate their brains, the process of brain donation, and how you can enroll to make this generous gift.*

**Gene Studies**

GeneMatch – [www.endalznow.org/genematch](http://www.endalznow.org/genematch)

*This program through the Alzheimer’s Prevention Registry (APR) uses genetic testing (through free cheek swab kits) to match volunteers with research opportunities (age 18+).*

**SUNY at Buffalo – CEAD serving the Western New York Region: Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans and Wyoming Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| 04437511 | Active, Not Enrolled | Ongoing | A study of Donanemab (LY3002813) in participants with early Alzheimer’s Disease (Trailblazer – ALZ 2) , (AACI) |
| 02720445 | Active, Enrolling | Ongoing | Memory Improvement through nicotine dosing (MIND Study) |
| 05063539 | Active/ Not Enrolling | Ongoing | MTAE – Not screening new patients |
| 01584440 | Active/Enrolling | Ongoing | Avanir |
| 05256134 | No | Ongoing | Roche – awaiting site initiation visit, as a center we are not enrolling |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**University of Rochester Memory Care Center – CEAD serving the Finger Lakes Region: Chemung, Livingston, Monroe, Ontario, Schuyler, Seneca, Steuben, Wayne and Yates Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name** |
| **Active Enrolling** | **Ongoing** |
| NCT02854033 | X |  | ADNI-3: Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (ADNI3) |
| NCT03108846 | X |  | S-CitAD:Escitalopram for Agitation in Alzheimer's Disease (S-CitAD) |
|  | X |  | APT Webstudy/Trial Ready Cohort (TRC) (ATRI) Subjects will be informed of their brain amyloid status |
| NCT03828747 | X |  | GN40040: This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. |
| NCT03887455 |  | X | Eisai BAN2401-301 (Eisai) Study assesses safety, tolerability, and efficacy of an experimental medication (BAN2401) in people with early Alzheimer’s disease. (CLARITY) |
| NCT03443973 |  | X | GRADUATE II Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) |
| NCT04374253 |  | X | POST-GRADUATE: An open-label, multicenter rollover study to evaluate the safety tolerability and efficacy of long-term gantenerumab administration in participants with Alzhiemer’s Disease |
| NCT03313895 | X |  | The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI |
| NCT02008357 |  | X | Anti-Amyloid treatment in Asymptomatic AD (A4) (ATRI) |
| None | X |  | Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) To find as many people as possible (also called a “cohort”) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer’s dementia |
| NCT04468659 | X |  | AHEAD 3-45 Study |

|  |  |  |  |
| --- | --- | --- | --- |
| NCT04488419 |  |  | Athira ATH-1017-AD-0203; Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease |
| NCT04241068 |  | X | EMBARK: A study to Evaluate Safety and Tolerability of Aducanumab in Participants with Alzheimer’s Disease who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 |
| NCT04437511 |  | X | TRAILBLAZER: A Study of Donanemab (LY3002813) in Participants with Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2) |
| NCT04381468 | X |  | Vaccinex; SEM4AD Blockade Safety and Brain Metabolic Activity in Alzheimer’s Disease (AD) (Signal-AD) |
| NCT04770220 | X |  | Alzheon; An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4) |
| NCT04994483 | X |  | CASSAVA; A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 weeks. |
| NCT05058950 | X |  | Biogen Intuition; An observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment from Normal Aging |
| NCT05256134 |  |  | Skyline: A study to evaluate safety and efficacy of Gantenerumab in patients at risk of developing Alzheimer’s Disease \*\*TO START ENROLLING Early 2023\*\* |
| NCT05310071 |  |  | ENVISION: A study to verify the clinical benefit of Aducanumab \*\*TO START ENROLLING Early 2023\*\* |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name** |
| **Active Enrolling** | **Ongoing** |
|  |  | X | Improving Well-Being for Older Adult Family Dementia Caregivers |
| ran | X |  | Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training in MCI (ACT study) |
|  |  | X | CogT TDCS study (BEEM) and Brain Imaging Study (BIS) |
|  |  |  |  |
|  |  |  |  |

**SUNY at Upstate Medical University – CEAD of the Central New York Region: Broome, Cayuga, Chenango, Cortland, Herkimer, Jefferson, Lewis, Madison, Oneida, Onondaga, Oswego, St. Lawrence, Tioga and Tompkins Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
|  |  |  |  |
| NCT02720445 | Active/  Recruiting | Yes | Memory Improvement Through Nicotine Dosing (MIND) Study |
| NCT04437511 | Active/Not recruiting | Yes | Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease (TRAILBLAZER ALZ 2) |
| NCT04374253 | Active/Not recruiting | Yes | An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (Post- Graduate) |
| NCT03919162 | Active/Recruting | Yes | A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND) |
| NCT04777409 | Active/Recruting | Yes | A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE Plus) |
| NCT04098666 | Pending |  | Metformin in Alzheimer’s Dementia Prevention (MAP)  *Projected start date January 2023* |
| NCT0492874 | Pending |  | A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer’s Disease (INVOKE)  *Projected start date January 2023* |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| None Reported |  |  |  |

**Albany Medical College – CEAD serving the Capital Region of New York: Albany, Columbia, Delaware, Fulton, Greene, Montgomery, Otsego, Rensselaer, Saratoga, Schoharie and Schenectady Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active**  **Enrolling** | **Ongoing** |
| 05026177 | X | X | RefocusALZ - Casasava PTI-125-06  A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer’s disease (AD) for 76 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and functional decline will be evaluated. |
| NCT04437511 |  | X | TRAILBLAZER-ALZ 2 is a Phase 3, double-blind, placebo-controlled study to evaluate the safety and efficacy of N3pG antibody (donanemab) in participants with early symptomatic AD (prodromal AD and mild dementia due to AD) with the presence of brain tau pathology. |
| NCT03887455 |  | X | Lecanemab-This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer’s disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluatethe long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in  the Extension Phase. |

|  |  |  |  |
| --- | --- | --- | --- |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| 050009524 | X | X | Interactive Physical and Cognitive Exercise Study (iPACES)  [Info@myipaces.org](mailto:Info@myipaces.org) |
| NCT02854033 |  | X | The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire Alzheimer’s disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO and ADNI-2).  \*Currently recruiting non-Caucasian participants only for the cognitively normal cohort. |

**Montefiore Health System – CEAD of the Hudson Valley Region: Dutchess, Orange, Putnam, Rockland, Sullivan, Ulster and Westchester Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| None Reported |  |  |  |
|  |  |  |  |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| NCT04404153 | yes | yes | Transcranial Direct Current Stimulation (tDCS) in Mild to Moderate Alzheimer’s Disease (AD) Patients |
| NCT04426539 | yes | yes | New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study |
| Montefiore/Einstein IRB | Yes | Yes | Nonlinguistic vocal biomarkers study |
| Montefiore/Einstein IRB | Yes | Yes | Life Story Club |

**SUNY at Stony Brook University – CEAD of the Long Island Region: Nassau and Suffolk Counties**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| None Reported |  |  |  |
|  |  |  |  |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
|  | Yes | Yes | [Cholinergic Study](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fnews.stonybrook.edu%2Fnewsroom%2Fpress-release%2Fgeneral%2F2018-06-06-alzheimers-foundation-of-america-grants-stony-brook-medicine-for-targeted-treatment%2F&data=04%7C01%7CDaphne.Perry%40stonybrookmedicine.edu%7C42ce63124ec44d27cbb708d925fb10b5%7Ceafa1b31b194425db36656c215b7760c%7C0%7C0%7C637582582509545791%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=DHihixAafVlRreMgUJ24RGffsaou0BCVE6I0lRqaW2k%3D&reserved=0) / VAT Study- Christine DeLorenzo, PhD, Principal Investigator  PET imaging research project comparing healthy brain neurons to those with Alzheimer’s.  This research hopes and increased understanding of how neurons become damaged will improve efforts toward drug development. |
|  | Yes | Yes | Caregiver Study – [Stephanie Brown, PhD, Principal Investigator](https://nam11.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.buffalo.edu%2Fubnow%2Fstories%2F2017%2F08%2Fspousal-caregiving.html&data=04%7C01%7CDaphne.Perry%40stonybrookmedicine.edu%7C42ce63124ec44d27cbb708d925fb10b5%7Ceafa1b31b194425db36656c215b7760c%7C0%7C0%7C637582582509555792%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=MBOLK9qNmh8Vff5YQMwy6pkBQYf3f%2FdhsVh%2FbJY1LHM%3D&reserved=0)  Research examining caregiving’s impact on your immune system  Hypothesis includes protective factors of caregiving  Recruiting caregivers at all stages of caregiving  ”Spouses who are caregivers show decreased immune function, increased signs of physiological stress and are at greater risk for physical and mental illness.”  BUT “the act of providing help to somebody is typically stress-relieving and is associated with better emotional and physical well-being.”  Dr. Brown research “has identified personal, interpersonal, and situational factors that unlock authentic caring behavior that is regulated within the brain, and releases hormones that protect the helper’s immune system. Her current work uses this information to identify ways that the physical environment and the social context can be used to prime activation of these “helping” neural circuits. She is currently studying caregivers of Alzheimer’s patients to identify ways to help people in this circumstance.” |

**SUNY at Downstate Medical Center –** **CEAD of the New York City Region: Boroughs of Bronx, Brooklyn, Manhattan, Queens, and Staten Island**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**New York University School of Medicine - CEAD of the New York City Region: Boroughs of Bronx, Brooklyn, Manhattan, Queens, and Staten Island**

For information, contact: 212-263-5845 • [anamika.mishra@nyulangone.org](mailto:anamika.mishra@nyulangone.org)

|  |  |  |  |
| --- | --- | --- | --- |
| ***Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| 02720445 | Enrolling | YES | Long-Term Nicotine Treatment of Mild Cognitive Impairment (MIND) |
| 03887455 | Active | YES | A study to confirm safety and efficiency of Lecanemab in Participants with Early Alzheimer’s Disease (Clarity AD) |
| 020008357 | No | YES | Clinical Trial of Solanezumab for Older Individuals who may be at risk for Memory Loss (A4) |
| 03919162 | Active | YES | A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficiency and Safety of Varoglutamstat (PQ912) in Patients with Early Alzheimer’s Disease (AD) with a Stage Gate to Phase 2B (VIVAMIND) |
| 04777409 | No | NO | A Research Study Investigating Semaglutide in People with Early Alzheimer’s Disease (EVOKE Plus) |
| 04777396 | No | No | A Research Study Investigating Semaglutide in People with Early Alzheimer’s Disease (EVOKE) |
| 03282916 | Enrolling | YES | Anti-viral therapy in Alzheimer’s disease |
| 04241068 | Active | YES | A study to evaluate safety and tolerability of Aducanumab in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 |
| 04619420 | Enrolling | YES | A Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (Autonomy) |
| 04098666 | YES | YES | Metformin in Alzheimer’s dementia Prevention (MAP) |
| 04437511 | Active | YES | A study of Donanemab (LY3002813) in Early Symptomatic Alzheimer’s Disease (TRAILBLAZER -ALZ2) |
| 04770220 | Enrolling | YES | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of Alz-801 in Subjects with Early Alzheimer’s Disease and APOE4/4 Genotype |
| 05399888 | No | No | A study to assess if BII080 can change clinical dementia rating-sum of boxes scores, and BII080 safety and tolerability when injected into the Cerebrospinal Fluid of participants with mild cognitive impairment due to Alzheimer’s Disease (AD) or Mild AD Dementia between 50 to 80 years of age (CELIA) |
| 05310071 | No | No | A study to verify the clinical benefit of Aducanumab in participants with early Alzheimer’s Disease (ENIVISION) |
| 03108846 | No | No | Escitalopram for agitation in Alzheimer’s Disease (S-CitAD) |
| 05267535 | No | No | Pirmelatine 20 Mg in participants with mild dementia due to Alzheimer’s Disease |
| Not available yet | No | No | Phase 1 Clinical Trial of Innate immunity stimulation via TLR9 in early AD |
| ***Non - Drug Trials*** | | | |
| **NCT #** | **Study Status** | | **Study Name/Description** |
| **Active Enrolling** | **Ongoing** |
| 02854033 | Enrolling | YES | Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) ATRI-001 |
| NA | Yes | Yes | A single-center longitudinal study of the diagnosis, clinical course, risk factors, causes and treatment of cognitive impairment in aging, Alzheimer’s Disease (AD) and related disorders |
| NA | Yes | Yes | Visual Biomarkers in Alzheimer’s Disease |
| 00286637 | Yes | Yes | Optical coherence domain reflectometry and optical coherence tomography measurements of intraocular structure (DOMAIN) |
| NA | Yes | Yes | Understanding CSF clearance in aging and Alzheimer’s Disease |
| NA | Yes | Yes | Improving oral health in persons with mild dementia |
| NA | Yes | Yes | Intracortical myelin deficits in early Alzheimer’s Disease |
| NA | Yes | Yes | Mechanisms of Age-Related White Matter Hyperintensities: Insights from Advanced MRI |
| NA | Yes | Yes | In vivo insights of small vessel changes with age using USPIO-enhanced MRI |
| NA | Yes | Yes | Resolvant |
| NA | Yes | Yes | Transcranial Photobiomodulation for Alzheimer’s Disease (TRAP-AD) |
| 04426539 | Yes | Yes | New IDEAS: Imaging Dementia – Evidence for Amyloid Scanning Study |
| 05058950 | Yes | Yes | An observational study using multimodal sensors to measure cognitive health in adults and distinguish mild cognitive impairment for normal aging (intuition) |

**Columbia University Medical Center - CEAD of the New York City Region: Boroughs of Bronx, Brooklyn, Manhattan, Queens, and Staten Island**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ***Drug Trials*** | | | | | | | |
| **NCT #** | | **Study Status** | | | | **Study Name/Description** | |
| **Active Enrolling** | | **Ongoing** | |
| 03887455 | |  | | X | | A Study to Confirm Safety and Efficacy of BAN2401 in Participants with Early Alzheimer's Disease CLARITY AD | |
| 03282916 | | X | |  | | Anti-viral therapy in Alzheimer’s disease. (VALAD) | |
| 04710030 | | X | |  | | Anti-viral therapy in Mild Cognitive Impairment. (VALMCI) | |
| 03108846 | | X | |  | | Escitalopram (NIA) Escitalopram for Agitation in Alzheimer’s disease. (S-CITAD) | |
| 03260920 | | X | |  | | A Phase 2 Clinical Trial of Oxytocin for Frontotemporal Dementia (FOXY) | |
| 02862210 | | X | |  | | Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia | |
| 02008357 | |  | | X | | A4 solanezumab (ADCS/Lilly) Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4). | |
| 04118764 | | X | |  | | Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound | |
| 04374136 | | X | |  | | A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients. (INFRONT-3) | |
| 04374253 | |  | | X | | A study to evaluate the safety, tolerability, and efficiency of long-term gantenerumab administration in participants with Alzheimer’s Disease (AD) (POST GRADUATE) | |
| 04141150 | |  | | X | | Evaluation of [18F] APN-1607 PET Uptake in Alzheimer’s Disease patients compared with healthy subjects | |
| 04993768 | |  | | X | | A Phase 2a Study of TPN-101 in patients with progressive supranuclear palsy (PSP) | |
| 04592874 | | X | |  | | A Phase 2 study for safety and tolerability of AL002 (INVOKE-2) | |
| 04993755 | | X | |  | | A Phase 2a study of TPN-101 in patients with C9ORF72 ALS/FTD | |
| 04468659 | | X | |  | | A study to evaluate efficiency and safety of treatment with Lecanemab in participants with preclinical AD and elevated amyloid and also in participants with early preclinical AD and intermediate amyloid (AHEAD 3-45) | |
| 04381468 | | X | |  | | SEMA4D Blockade safety and brain metabolic activity in Alzheimer’s Disease (SIGNAL-AD) | |
| 04931459 | | X | |  | | A study to evaluate the safety, tolerability, and blood levels of ACU193 in participants with MCI or Mild AD (INTERCEPT-AD) | |
| ***Non - Drug Trials*** | | | | | | | |
| **NCT #** | | **Study Status** | | | | **Study Name/Description** | |
| **Active Enrolling** | | **Ongoing** | |
| 03507257 | | X | |  | | Longitudinal Early Onset Alzheimer’s Disease (LEADS) | |
| 04239079 | | X | |  | | Autoimmune features in neurodegenerative disorders (AD Autoimmune) | |
| 00869817 | |  | | X | | Dominantly Inherited Alzheimer Network (DIAN) | |
|  | | X | |  | | Genetic Study of Alzheimer’s Disease in Caribbean Hispanics (EFIGA) | |
|  | | X | |  | | Characterizing Subjective Cognitive Decline in Older Adults (SCD) | |
| 04363684 | |  | | X | | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Protocol (ALLFTD) | |
|  | | X | |  | | Targeting Lewy Body Specific Pathology Using Biomarkers (TLB) | |
|  | | X | |  | | Neurodegeneration-Associated Psychiatric Symptoms (NAPS) | |
|  | |  | | X | | Long Life Family Study (LLFS) | |
|  | |  | | X | | Washington Height Inwood Biomarker Study (WHICAP) | |